There is no defensible universal winner in the public evidence reviewed. Build the shortlist around the required product, access route, destination states and operational responsibilities, then verify performance privately.
Useful starting points include:
| Need | Evidence-supported starting point | What remains unverified |
|---|---|---|
| Lilly-linked patient access | Lilly’s support page identifies Gifthealth, FuzeHealth and Amazon Pharmacy for home delivery, and Walmart Pharmacy for pickup | Whether your proposed integration, products and patient population are supported. (lilly.com) |
| Novo-linked self-pay dispensing | NovoCare’s terms identify CenterWell, CoAssist and BlinkRx network pharmacies | Which legal entity fills each patient’s order and what reporting is available. (novocare.com) |
| Clinic-owned purchasing | A licensed, authorized wholesaler assessed for the exact transaction | Account eligibility, product allocation and clinic acquisition price. (fda.gov) |
Suggested scoring after eligibility and quality gates: continuity 30%, workflow 25%, patient experience 20%, attributable cost 15%, and exit flexibility 10%. These are proposed weights, not validated industry standards.
Do not infer spare capacity or better service from inclusion in a manufacturer network.
Explore the table row by row
A working view of the research
Lilly-linked patient access
- Evidence-supported starting point
- Lilly’s support page identifies Gifthealth, FuzeHealth and Amazon Pharmacy for home delivery, and Walmart Pharmacy for pickup
- What remains unverified
- Whether your proposed integration, products and patient population are supported. (lilly.com)
Sources cited on this page
- lilly.com · Source 1 ↗https://www.lilly.com/lillydirect/rx-support
- novocare.com · Source 2 ↗https://www.novocare.com/eligibility/delivery.html
- fda.gov · Source 3 ↗https://www.fda.gov/drugs/drug-supply-chain-integrity/check-licensure-wholesale-drug-distributors-and-third-party-logistics-providers?utm_source=openai